Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of a 14- Valent Recombinant Human Papillomavirus Vaccine (SCT1000) in Healthy Women Aged 18-45 Years

NCT06041061 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT06041061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of a 14- Valent Recombinant Human Papillomavirus Vaccine (SCT1000) in Healthy Women Aged 18-45 Years
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 13, 2023
Completion date
August 31, 2028
Enrollment
18,000 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hpv infection, hpv-related carcinoma